Kathleen Dorritie

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 359 citations · Full text

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Tanya Siddiqi, David G. Maloney, Saad S. Kenderian et al. · The Lancet · 2023 · 174 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Transcend Cll 004 +9

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Michael Boyiadzis, Mounzer Agha, Robert L. Redner et al. · Cytotherapy · 2017 · 170 citations

Hematological Malignancy, Cell Therapy, Medicine +11

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Yucai Wang, Preetesh Jain, Frederick L. Locke et al. · Journal of Clinical Oncology · 2023 · 155 citations · Full text

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie et al. · Blood · 2021 · 116 citations · Full text

Immunology, Prior Therapies, Pathology +20